BioNTech SE (BNTX) Receives a Hold from Jefferies

Jefferies analyst Akash Tewari maintained a Hold rating on BioNTech SE (BNTXResearch Report) today and set a price target of $230.00. The company’s shares closed last Friday at $174.64.

According to, Tewari is a 5-star analyst with an average return of 30.3% and a 66.7% success rate. Tewari covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Madrigal Pharmaceuticals, and BioMarin Pharmaceutical.

Currently, the analyst consensus on BioNTech SE is a Moderate Buy with an average price target of $286.00.

See the top stocks recommended by analysts >>

BioNTech SE’s market cap is currently $40.02B and has a P/E ratio of 4.47.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.

Read More on BNTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More